Je. Levine et al., Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD, BONE MAR TR, 25(1), 2000, pp. 13-18
Citations number
17
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Between October 1995 and October 1998, 24 children aged 9 months to 17 year
s (median 11 years) underwent cytokine-mobilized allogeneic peripheral bloo
d stem cell (PBSC) transplantation for treatment of hematological disorders
. All of the transplants were the first allogeneic transplant for the recip
ient. Twenty patients were transplanted for hematological malignancies (ALL
= 8, AML = 6, CML = 4, MDS = 2) and four patients were transplanted for no
n-malignant disease (thalassemia major = 2, Wiskott-Aldrich syndrome = 1, K
ostmann's syndrome = 1). Nineteen donors were HLA-identical siblings, four
were HLA-matched or single antigen mismatched parents, and one was a syngen
eic transplant. Donors aged 8 to 38 years (median 15 years, 14 donors <18 y
ears) received G-CSF 10 mu g/kg/day subcutaneously beginning 4 days before
PBSC collection and were submitted to one to three leukapheresis collection
s. The median CD34(+) cell yield was 7.8 x 10(6) cells/kg recipient body we
ight. All patients achieved an ANC >0.5 x 10(9)/l after a median of 13 days
(range 10-21), Twenty-three patients eventually achieved platelet transfus
ion independence. One patient died on day 63 without ever achieving platele
t transfusion independence. Four patients received platelet transfusions to
maintain a platelet count well above 20 x 10(9)/l due to bleeding complica
tions. Of the 19 evaluable patients, the median time to a non-transfused pl
atelet count of 20 x 10(9)/l was 12 days (range 0-44), Ten of 23 at-risk pa
tients developed acute GVHD grades II to IV, with grades III to IV in four
patients. Twelve of 19 patients followed for at least 100 days have develop
ed chronic GVHD (extensive = 2, limited = 10) with an actuarial risk of chr
onic GVHD of 75% at 1 year. The Kaplan-Meier estimate of event-free surviva
l is 65% at 2 years. Four patients died (GVHD = 3, VOD = 1), three patients
relapsed, and one patient with thalassemia major had a late graft failure
with autologous recovery. Based upon our experience, allogeneic PBSCT is sa
fe for both pediatric donors and recipients and engraftment of neutrophils
and platelets is rapid.